



Biotech Daily

Tuesday October 20, 2009

Daily news on ASX-listed biotechnology companies

- * **ASX, BIOTECH UP: CATHRX UP 23%; BIOTA DOWN 13.5%**

- * **EVADO SUPPORTS MALAYSIAN BOWEL CANCER SCREEN**

- * **CAPITAL GROUP BUYS 5.6m MORE CSL SHARES**

- * **CATHRX PLEADS SCHULTZ TO ASX 117% QUERY**

- * **CORRECTION: LIVING CELL DIRECTORS PAID CASH, PLUS OPTIONS**

MARKET REPORT

The Australian stock market was up 1.12 percent on Tuesday October 20, 2009 with the S&P ASX 200 climbing 53.4 points to 4846.2 points.

Seventeen of the Biotech Daily Top 40 stocks were up, 13 fell, eight traded unchanged and two were untraded.

Cathrx was best for the third trading day in a row, up a further 14 cents or 23.3 percent to 74 cents with 210,835 shares traded, followed by Acrux up 13.8 percent to \$2.10 and Cytopia up 10 percent to 11 cents.

Phylogica climbed 8.7 percent; Chemgenex, Uscom and Viralytics were up more than six percent; Cellestis and Prana rose more than five percent; Nanosonics, Optiscan and Psivida were up more than four percent; Genera and Living Cell were up more than three percent; Bone and Universal Biosensors rose more than two percent; with Pharmaxis up 1.2 percent.

Biota led the falls, down 45 cents or 13.5 percent to \$2.88 with 3.15 million shares traded.

Antisense and Impedimed lost more than five percent; Benitec, Phosphagenics and Tissue Therapies fell more than four percent; Bionomics, Mesoblast and Progen shed more than three percent; with Novogen down 1.6 percent.

EVADO

Evado says its clinical trials software will support the first screen for colorectal cancer in Malaysia.

Evado said its software would enable clinicians to keep track of clinical data from up to 5000 subjects from low-income areas.

The company said that Malaysia's Empowered Foundation, with assistance from the Malaysian Health Department, local government and industry partners, was running the study to prevent cancer among Malaysia's poor.

Evado chief executive Jennie Anderson said Empowered Foundation founder Dr Christine Ng needed a web-based clinical system to collect clinical health and medical device data and her company's software was specifically designed for this purpose.

"Evado Registry will provide a central repository for all of Empowered's study data," Ms Anderson said.

"The Empowered study has the potential of saving many lives and we are delighted to be providing a database for this study," Ms Anderson said.

Evado said Malaysian university students would canvas potential registry subjects in poorer areas of Malaysia, the study would be explained and samples collected and analyzed.

The company said any people with suspected colon cancer would be contacted for further investigations. All data will be entered into Evado's Registry software.

Evado said the Registry enabled users to access a web-based interface.

The company said data collection and timing points facilitated the collection of longitudinal health records to track patient health outcomes over time, which would be "especially useful for the Malaysian bowel cancer screen".

Evado is a private company.

CSL

The US based Capital Group Companies has increased its substantial shareholder in CSL by 5,591,737 shares to 6.5 percent of the company.

Capital Group became substantial on September 11, 2009 with a holding of 32,199,306 shares or 5.43 percent.

Capital Group said the shares were bought at an average price of \$33.7204 per share.

The Capital Group said it did not own shares in CSL but held them on account for Capital Research and Management Company.

CSL fell six cents or 0.2 percent to \$31.90 with 2.8 million shares traded.

CATHRX

Cathrx has told the ASX that it was not aware of any information it had not announced which, if known, could explain recent trading in its securities.

The ASX said the company's share price rose from 36 cents on October 14, 2009 to 78 cents, a 116.6 percent increase, on October 20 and noted an increase in trading volume.

Cathrx said it presented at the annual Wilson HTM life sciences conference on October 13, 2009 and there had been "some media commentary following that presentation".

Cathrx was up 14 cents or 23.3 percent to 74 cents.

LIVING CELL TECHNOLOGIES

Last night's article on Living Cell's vote on the issue of 1,300,000 unlisted options to three directors, said it was "apparently in lieu of directors' pay".

In the explanatory notes attached to the notice of meeting Living Cell said the 400,000 options each to Robert Finder and David McAuliffe would form "a component" of the directors' remuneration.

Living Cell chief executive officer Dr Paul Tan confirmed to Biotech Daily that the options were in addition to their directors' fees of \$50,000 a year each and were an incentive to attract good directors.

Living Cell was up one cent or 3.45 percent to 30 cents.